These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 6426051

  • 1. The effect of auranofin on polymorphonuclear granulocytes.
    Hafström I.
    Scand J Rheumatol Suppl; 1983; 51():36-41. PubMed ID: 6426051
    [Abstract] [Full Text] [Related]

  • 2. Correlation of in vitro and in vivo effects of gold compounds on leukocyte function: possible mechanisms of action.
    Wolach B, DeBoard JE, Coates TD, Baehner RL, Boxer LA.
    J Lab Clin Med; 1982 Jul; 100(1):37-44. PubMed ID: 6283001
    [Abstract] [Full Text] [Related]

  • 3. Effects of auranofin on leukotriene production and leukotriene stimulated neutrophil function.
    Hafström I, Ringertz B, Palmblad J, Malmsten C.
    Agents Actions; 1984 Dec; 15(5-6):551-5. PubMed ID: 6099693
    [Abstract] [Full Text] [Related]

  • 4. Auranofin affects early events in human polymorphonuclear neutrophil activation by receptor-mediated stimuli.
    Hafström I, Seligmann BE, Friedman MM, Gallin JI.
    J Immunol; 1984 Apr; 132(4):2007-14. PubMed ID: 6321596
    [Abstract] [Full Text] [Related]

  • 5. Modulation of neutrophil functions by auranofin. Studies on effects in vitro and in rheumatoid arthritis patients.
    Hafström I, Udén AM, Palmblad J.
    Scand J Rheumatol; 1983 Apr; 12(2):97-105. PubMed ID: 6407101
    [No Abstract] [Full Text] [Related]

  • 6. Auranofin modulates mast cell histamine and polymorphonuclear leukocyte collagenase release.
    Wojtecka-Lukasik E, Sopata I, Maśliński S.
    Agents Actions; 1986 Apr; 18(1-2):68-70. PubMed ID: 2425596
    [Abstract] [Full Text] [Related]

  • 7. The mechanism of action of the antiinflammatory agents dexamethasone and Auranofin in human polymorphonuclear leukocytes.
    Coates TD, Wolach B, Tzeng DY, Higgins C, Baehner RL, Boxer LA.
    Blood; 1983 Nov; 62(5):1070-7. PubMed ID: 6313097
    [Abstract] [Full Text] [Related]

  • 8. Effects of gold compounds on function of phagocytic cells. Comparative inhibition of activated polymorphonuclear leukocytes and monocytes from rheumatoid arthritis and control subjects.
    Davis P, Johnston C.
    Inflammation; 1986 Sep; 10(3):311-20. PubMed ID: 3017859
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of lysosomal enzyme release from rat leukocytes by auranofin. A new chrysotherapeutic agent.
    Dimartino MJ, Walz DT.
    Inflammation; 1977 Jun; 2(2):131-42. PubMed ID: 104927
    [Abstract] [Full Text] [Related]

  • 10. The effect of piroxicam and auranofin on cell migration.
    Rueda HA, Scheinberg MA.
    Clin Rheumatol; 1985 Mar; 4(1):68-72. PubMed ID: 3921306
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Changes in mononuclear cell function in patients with rheumatoid arthritis following treatment with auranofin.
    Coughlan RJ, Richter MB, Panayi GS.
    Clin Rheumatol; 1984 Mar; 3 Suppl 1():25-32. PubMed ID: 6432410
    [Abstract] [Full Text] [Related]

  • 13. Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis.
    Furst DE.
    Pharmacotherapy; 1983 Mar; 3(5):284-98. PubMed ID: 6417628
    [Abstract] [Full Text] [Related]

  • 14. Comparison of auranofin and aurothioglucose in the treatment of rheumatoid arthritis: a single blind study.
    van Riel PL, van de Putte LB, Gribnau FW, Macrae KD.
    Clin Rheumatol; 1984 Mar; 3 Suppl 1():51-6. PubMed ID: 6432414
    [Abstract] [Full Text] [Related]

  • 15. II. Unbound versus total serum gold concentration: pharmacological actions on cellular function.
    Lorber A, Kunishima DH, Harralson AF, Simon TM.
    J Rheumatol; 1983 Aug; 10(4):568-73. PubMed ID: 6413684
    [Abstract] [Full Text] [Related]

  • 16. Auranofin: experience to date.
    Blodgett RC.
    Am J Med; 1983 Dec 30; 75(6A):86-9. PubMed ID: 6419601
    [Abstract] [Full Text] [Related]

  • 17. Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.
    Chaffman M, Brogden RN, Heel RC, Speight TM, Avery GS.
    Drugs; 1984 May 30; 27(5):378-424. PubMed ID: 6426923
    [Abstract] [Full Text] [Related]

  • 18. Auranofin therapy in rheumatoid arthritis.
    Bernhard GC.
    J Lab Clin Med; 1982 Aug 30; 100(2):167-77. PubMed ID: 6808066
    [Abstract] [Full Text] [Related]

  • 19. Review of auranofin, an oral chrysotherapeutic agent.
    Delafuente JC, Osborn TG.
    Clin Pharm; 1984 Aug 30; 3(2):121-7. PubMed ID: 6426843
    [Abstract] [Full Text] [Related]

  • 20. [Auranofin. Mechanism of action, pharmacokinetics and clinical use. Comparison with injectable gold salts].
    Chamouard JM, Clerc D, Bisson M, Medicis P, Massias P.
    Rev Rhum Mal Osteoartic; 1985 Apr 30; 52(4):277-82. PubMed ID: 3923604
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.